Fort Wayne Medical Oncology and Hematology

Clinical research site in Fort Wayne, Indiana · 2514 E DUPONT RD STE 100, FORT WAYNE, IN 46825-1619 · (260) 484-8830 · Website

As of July 2026, 24 paid clinical trials are recruiting at Fort Wayne Medical Oncology and Hematology in Fort Wayne, Indiana. Active studies at this site cover conditions such as Breast Cancer, Melanoma and Advanced Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Fort Wayne Medical Oncology and Hematology (24)

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

for Non-small Cell Lung Cancer (NSCLC)

37 locations incl. Daphne

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07361497·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for Melanoma

93 locations incl. Chandler

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06246916·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

129 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

for Breast Neoplasms

59 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06966700·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for Carcinoma, Non-Small Cell Lung

104 locations incl. Anchorage

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04389632·Phase 1·Recruiting·Listed May 2020

Apply to this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

79 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

for Follicular Lymphoma (FL)

32 locations incl. Fresno

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT06191744·Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

60 locations incl. Gilbert

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for Diffuse Large B-Cell Lymphoma

46 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06717347·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

for Mantle Cell Lymphoma

41 locations incl. Birmingham

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06742996·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

27 locations incl. Phoenix

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT05650632·Phase 1·Recruiting·Listed Dec 2022

Apply to this trial

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

for Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

27 locations incl. Los Angeles

Sponsor: Bayer

Sex: All·Age: All ages

Code: NCT04142437·Recruiting·Listed Oct 2019

Apply to this trial

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

for Extensive-stage Small-cell Lung Cancer

32 locations incl. Tucson

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT06712355·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

for Non-small Cell Lung Cancer

39 locations incl. Birmingham

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT06712316·Phase 2, Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

for Non Small Cell Lung Cancer

46 locations incl. Dothan

Sponsor: OncoC4, Inc.

Sex: All·Age: 18+

Code: NCT05671510·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

for Urothelial Cancer

11 locations incl. Santa Barbara

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: 18+

Code: NCT07566156·Phase 3·Recruiting·Listed May 2026

Apply to this trial

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

for HR+/HER2- Breast Cancer

21 locations incl. Birmingham

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT07492641·Phase 3·Recruiting·Listed Mar 2026

Apply to this trial

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

for Small-cell Lung Cancer

13 locations incl. Denver

Sponsor: IDEAYA Biosciences

Sex: All·Age: 18+

Code: NCT07174583·Phase 1, Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

for Small Cell Lung Cancer

10 locations incl. New Haven

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07155174·Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

for Multiple Myeloma

17 locations incl. Scottsdale

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07095452·Phase 2, Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

for Non-Small Cell Lung Cancer

20 locations incl. Duarte

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT05005403·Phase 1·Recruiting·Listed Aug 2021

Apply to this trial

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

for Breast Cancer

15 locations incl. Orlando

Sponsor: Incyclix Bio

Sex: All·Age: 18+

Code: NCT05735080·Phase 1, Phase 2·Recruiting·Listed Feb 2023

Apply to this trial

A Study of HS-20110 in Participants With Advanced Solid Tumors

for Solid Tumors

7 locations incl. Tamarac

Sponsor: Hansoh BioMedical R&D Company

Sex: All·Age: 18+

Code: NCT06892379·Phase 1·Recruiting·Listed Mar 2025

Apply to this trial

BostonGene and Exigent Genomic INsight Study

for Breast Cancer

7 locations incl. Rogers

Sponsor: BostonGene

Sex: All·Age: 18+

Code: NCT06272864·Recruiting·Listed Feb 2024

Apply to this trial

More research sites in Fort Wayne

Parkview Research Center (12 trials)
Parkview Regional Medical Center (8 trials)
Parkview Research Center at Parkview Regional Medical Center (8 trials)
Parkview Health (4 trials)
Fort Wayne Medical Oncology and Hematology, Inc (3 trials)
GSK Investigational Site (2 trials)
Lutheran Medical Group (2 trials)
Parkview Cancer Institute (2 trials)
Parkview Packnett Family Cancer Institute (2 trials)
Salus Research, Inc. (2 trials)

Explore more

Paid clinical trials in Fort Wayne, IN · Indiana clinical trials